Results 1 to 10 of about 73,005 (301)
Carrier-Protein-Free Pneumococcal Glycoconjugate Vaccines Enabled by SPAAC: Serotype 15C CPS–PADRE Conjugates and the Impact of an RR Cleavage Motif [PDF]
VaccinesBackground/Objectives: Polysaccharide-protein conjugate vaccines have proven highly effective, yet they remain limited by manufacturing complexity, cost, and variable performance across serotypes, while carrier proteins can add unwanted immunological and
Huimin Yang +5 more
doaj +2 more sources
Current Scientific Advances in Vaccines Against UTIs: Challenges and Prospects [PDF]
MicroorganismsUrinary Tract Infection (UTI), the second most common infectious disease globally, poses a particularly significant threat to adult female populations. Epidemiological data show that Uropathogenic Escherichia coli (UPEC) is responsible for approximately ...
Baoying Wang +8 more
doaj +2 more sources
Frontiers in Molecular Biosciences, 2023 Vaccines are cost-effective tools for reducing morbidity and mortality caused by infectious diseases. The rapid evolution of pneumococcal conjugate vaccines, the introduction of tetravalent meningococcal conjugate vaccines, mass vaccination campaigns in ...
Francesca Micoli +4 more
doaj +1 more source
Vaccines against Meningococcal Diseases
Microorganisms, 2020 Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza +2 more
doaj +1 more source
Vaccine hesitancy and receipt of mandatory and optional pediatric vaccines in Shanghai, China
Human Vaccines & Immunotherapeutics, 2022 Given increased global concern about vaccine hesitancy, this study estimates coverage of mandatory vs non-mandatory vaccines in children, and assesses whether vaccine hesitancy among young parents relates to their childʻs eventual vaccination status in ...
Mengdi Ji +3 more
doaj +1 more source
iScience, 2022 Summary: Several effective SARS-CoV-2 vaccines have been developed using different technologies. Although these vaccines target the isolates collected early in the pandemic, many have protected against serious illness from newer variants.
Puthupparampil V. Scaria +9 more
doaj +1 more source
Journal of Epidemiology and Global Health, 2019 Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at
Atef Shibl +4 more
doaj +1 more source
Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.
Acta Médica Portuguesa, 2004 The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós +3 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2022 Use of pneumococcal conjugate vaccines (PCVs) has greatly reduced the incidence of invasive pneumococcal disease (IPD). V114 (VAXNEUVANCE™, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc.
Salini Mohanty +5 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2018 The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler +2 more
doaj +1 more source